4D Molecular Therapeutics Announces 2024 Annual Meeting of Stockholders
Ticker: FDMT · Form: DEF 14A · Filed: Apr 10, 2024 · CIK: 1650648
| Field | Detail |
|---|---|
| Company | 4d Molecular Therapeutics, INC. (FDMT) |
| Form Type | DEF 14A |
| Filed Date | Apr 10, 2024 |
| Risk Level | low |
| Pages | 15 |
| Reading Time | 19 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 4D Molecular Therapeutics, DEF 14A, Annual Meeting, Proxy Statement, PricewaterhouseCoopers
TL;DR
<b>4D Molecular Therapeutics will hold its 2024 Annual Meeting of Stockholders online on May 21, 2024, to elect a director and ratify the auditor.</b>
AI Summary
4D Molecular Therapeutics, Inc. (FDMT) filed a Proxy Statement (DEF 14A) with the SEC on April 10, 2024. The 2024 Annual Meeting of Stockholders for 4D Molecular Therapeutics, Inc. will be held online on May 21, 2024. The meeting will include the election of one Class I director for a term until the 2027 annual meeting. Stockholders will vote to ratify the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for fiscal year ending December 31, 2024. The record date for stockholders entitled to vote is April 3, 2024. The meeting will be held entirely online at www.virtualshareholdermeeting.com/FDMT2024.
Why It Matters
For investors and stakeholders tracking 4D Molecular Therapeutics, Inc., this filing contains several important signals. This filing is a proxy statement (DEF 14A) detailing the agenda and procedures for the annual shareholder meeting, which is crucial for corporate governance and shareholder participation. The online format aims to increase participation and reduce costs for both the company and its stockholders.
Risk Assessment
Risk Level: low — 4D Molecular Therapeutics, Inc. shows low risk based on this filing. The filing is a routine proxy statement for an annual meeting and does not contain new financial or operational information that would indicate significant risk.
Analyst Insight
Stockholders should review the proxy materials to understand the proposals and vote accordingly, particularly regarding director elections and auditor ratification.
Key Numbers
- May 21, 2024 — Annual Meeting Date (Date of the 2024 Annual Meeting of Stockholders)
- April 3, 2024 — Record Date (Stockholders of record as of this date are entitled to vote)
- 2027 — Director Term End (The elected Class I director will hold office until the 2027 annual meeting)
- December 31, 2024 — Fiscal Year End (Fiscal year for which PricewaterhouseCoopers LLP is being ratified as auditor)
Key Players & Entities
- 4D Molecular Therapeutics, Inc. (company) — Registrant name
- May 21, 2024 (date) — Date of Annual Meeting
- April 3, 2024 (date) — Record date for stockholders
- PricewaterhouseCoopers LLP (company) — Independent registered public accounting firm
- December 31, 2024 (date) — Fiscal year end for auditor ratification
- 2027 (date) — Term for elected director
- 5858 Horton Street #455 (address) — Company business address
- Emeryville, CA 94608 (address) — Company business address
FAQ
When did 4D Molecular Therapeutics, Inc. file this DEF 14A?
4D Molecular Therapeutics, Inc. filed this Proxy Statement (DEF 14A) with the SEC on April 10, 2024.
What is a DEF 14A filing?
A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by 4D Molecular Therapeutics, Inc. (FDMT).
Where can I read the original DEF 14A filing from 4D Molecular Therapeutics, Inc.?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by 4D Molecular Therapeutics, Inc..
What are the key takeaways from 4D Molecular Therapeutics, Inc.'s DEF 14A?
4D Molecular Therapeutics, Inc. filed this DEF 14A on April 10, 2024. Key takeaways: The 2024 Annual Meeting of Stockholders for 4D Molecular Therapeutics, Inc. will be held online on May 21, 2024.. The meeting will include the election of one Class I director for a term until the 2027 annual meeting.. Stockholders will vote to ratify the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for fiscal year ending December 31, 2024..
Is 4D Molecular Therapeutics, Inc. a risky investment based on this filing?
Based on this DEF 14A, 4D Molecular Therapeutics, Inc. presents a relatively low-risk profile. The filing is a routine proxy statement for an annual meeting and does not contain new financial or operational information that would indicate significant risk.
What should investors do after reading 4D Molecular Therapeutics, Inc.'s DEF 14A?
Stockholders should review the proxy materials to understand the proposals and vote accordingly, particularly regarding director elections and auditor ratification. The overall sentiment from this filing is neutral.
Risk Factors
- Proxy Statement Filing [low — regulatory]: The filing is a standard DEF 14A proxy statement, which is a routine disclosure for annual shareholder meetings.
Key Dates
- 2024-05-21: Annual Meeting of Stockholders — To elect a director and ratify the independent auditor.
- 2024-04-10: Filing Date — Date the Definitive Proxy Statement was filed with the SEC.
- 2024-04-03: Record Date — Determines which stockholders are eligible to vote at the Annual Meeting.
Filing Stats: 4,633 words · 19 min read · ~15 pages · Grade level 12 · Accepted 2024-04-10 16:05:22
Key Financial Figures
- $0.0001 — ies of 4DMT are shares of common stock, $0.0001 par value per share (the “common
Filing Documents
- edge20023177x1_def14a.htm (DEF 14A) — 584KB
- edge20023177x1_pc01.jpg (GRAPHIC) — 573KB
- edge20023177x1_pc02.jpg (GRAPHIC) — 503KB
- 0001140361-24-019090.txt ( ) — 2067KB
EXECUTIVE COMPENSATION
EXECUTIVE COMPENSATION ​ ​ 25 2023 Summary Compensation Table ​ ​ 25 Outstanding Equity Awards at 2022 Fiscal Year End ​ ​ 26 Narrative to Summary Compensation Table ​ ​ 26 Other Elements of Compensation ​ ​ 27
Executive Compensation Arrangements
Executive Compensation Arrangements ​ ​ 27
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT ​ ​ 30 DELINQUENT SECTION 16(a) REPORTS ​ ​ 32 ADDITIONAL INFORMATION ​ ​ 33 Householding of Proxy Materials ​ ​ 33 Other Matters ​ ​ 33 i TABLE OF CONTENTS 4D MOLECULAR THERAPEUTICS, INC. 5858 Horton Street #455 Emeryville, CA 94608 PROXY STATEMENT FOR THE 2024 ANNUAL MEETING OF STOCKHOLDERS MAY 21, 2024 We have sent you this Proxy Statement and the enclosed Proxy Card because the Board of Directors (the “Board”) of 4D Molecular Therapeutics, Inc. (referred to herein as the “Company”, “4DMT”, “we”, “us” or “our”) is soliciting your proxy to vote at our 2024 Annual Meeting of Stockholders (the “Annual Meeting”) to be held on Tuesday, May 21, 2024, at 1:00 p.m. Pacific time, virtually at www.virtualshareholdermeeting.com/FDMT2024. There will be no physical meeting location. The meeting will only be conducted via an audio webcast. • This Proxy Statement summarizes information about the proposals to be considered at the Annual Meeting and other information you may find useful in determining how to vote. • The Proxy Card is the means by which you actually authorize another person to vote your shares in accordance with your instructions. In addition to solicitations by mail, our directors, officers and employees, without additional remuneration, may solicit proxies by telephone, e-mail and personal interviews. We may retain outside consultants to solicit proxies on our behalf as well. All costs of solicitation of proxies will be borne by us. Brokers, custodians and fiduciaries will be requested to forward proxy soliciting material to the owners of stock held in their names, and we will reimburse them for their reasonable out-of-pocket expenses incurred in connection with the distribution of pr